Teva Pharmaceutical Industries Ltd. today announced that it has completed the purchase of 4.61 percent of all outstanding shares of Mylan N.V.
--(BUSINESS WIRE)--Jun. 19, 2015--
Teva Pharmaceutical Industries Ltd.
(NYSE and TASE: TEVA) today announced that it has completed the purchase of 4.61 percent of all outstanding shares of
(NASDAQ: MYL), which will enable Teva to commence proceedings before the Dutch Enterprise Chamber, should it become necessary.
Teva has advised Stichting Preferred Shares Mylan that if the Mylan Extraordinary General Meeting (“EGM”) on the
transaction is held no later than
August 31, 2015
, Teva will limit its aggregate shareholding in Mylan prior to the EGM to less than 5 percent of the outstanding shares of Mylan.
Greenhill & Co.
are serving as financial advisors to Teva.
Sullivan & Cromwell LLP
is serving as legal counsel to Teva, with
De Brauw Blackstone Westbroek N.V.
acting as legal advisor in